Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INBRX 105

Next Previous
Drug Profile

INBRX 105

Alternative Names: ES 101; INBRX-105; INBRX-105 - PDL1x41BB antibody

Latest Information Update: 30 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inhibrx
  • Developer Elpiscience Biopharmaceuticals; Inhibrx
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 03 Oct 2024 Inhibrx Biosciences terminates a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) due to lack of meaningful efficacy signal (NCT03809624)
  • 03 Oct 2024 Inhibrx Biosciences terminates a phase I trial in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in USA (IV) due to lack of meaningful efficacy signal (NCT03809624)
  • 30 May 2024 Inhibrx Biosciences acquires INBRX 105 from Inhibrx prior to May 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top